Objective: To analyze the rate of axillary recurrences and survival in patients operated on for breast cancer who had not undergone an axillary lymph node dissection (ALND) because of a negative sentinel node biopsy. Methods: The study includes 97 patients operated on for breast cancer and selective node biopsy from June 2000 to December 2001 who had a negative sentinel node biopsy and did not undergo ALND. Mean age was 58.2 years (55.9–60.5). Follow-up was done up to 5 years. After surgery all patients underwent clinical examination. Complementary treatment depended on the hospital protocol. Rate of axillary recurrences, presence of distant metastases and survival (Kaplan-Meier method) were studied. Results: After a median follow-up of 4.1 years (2.18–5.25), only 2/95 patients (2.1%) developed distant metastases. Four patients died but only the death of the patient who presented multiple metastases was related to the primary breast cancer (1%). The 5-year overall survival rate was 96%. Conclusions: (1) Only 1/95 patients studied developed nodal extra-axillary recurrence together with distant metastases. (2) The results obtained support the selective sentinel node biopsy as an accurate technique in the axillary stratification of patients with breast cancer, offering in the cases of negative sentinel node biopsy a safe axillary control after a 5-year follow-up.

Keywords:
Breast cancer, Sentinel node, Axillary lymph node dissection, Axillary recurrence
1.
Boring CC, Squieres TS, Tong T: Cancer statistics. Cancer 1991;41:19–36.
2.
Miltenburg DM, Miller C, Karamlou TB, Brunicardi FC: Meta-analysis of sentinel lymph node biopsy in breast cancer. J Surg Res 1999;84:138–142.
3.
Fisher B, Redmond C, Fisher ER, et al: Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl J Med 1985;312:674–681.
4.
Giulano AE, Haigh PI, Brennan MB, et al: Prospective observational study of sentinel lymphadenectomy without further axillary dissection in patients with sentinel node-negative breast cancer. J Clin Oncol 2000;13:2553–2559.
5.
Greco M, Agresti R, Raselli R, Giovanazzi R, Veronesi U: Axillary dissection can be avoided in selected breast cancer patients: analysis of 401 cases. Anticancer Res 1996;16:3913–3918.
6.
Greco M, Agresti R, Cascinelli N, et al: Breast cancer patients treated without axillary surgery. Clinical implications and biologic analysis. Ann Surg 2000;232:1–7.
7.
De Kanter AY, Menke-Pluymers MM, Wouters MWJM, Burgmans I, van Geel AN, Eggermont AMM: 5-year follow-up of sentinel node negative breast cancer patients. Eur J Surg Oncol 2006;32:282–286.
8.
Kjaergaard J, Blichert-Toft M, Andersern JA, Rank F, Pedersen BV: Probability of false negative nodal staging in conjunction with partial axillary dissection in breast cancer. Br J Surg 1985;72:365–367.
9.
Kokke MC, Jannink I, Barneveld PC, et al: Incidence of axillary recurrence in 113 sentinel node negative breast cancer patients: a 3-year follow-up study. Eur J Surg Oncol 2005;31:221–225.
10.
Krag DN, Weaver DL, Alex JC, Fairbank JT: Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe. Surg Oncol 1993;2:335–339.
11.
Langer I, Marti WR, Guller U, et al: Axillary recurrence rate in breast cancer patients with negative sentinel lymph node (SLN) or SLN micrometastases. Ann Surg 2005;241:152–158.
12.
Smidt ML, Janssen CM, Kuster DM, Bruggink ED, Strobbe LJ: Axillary recurrence after a negative sentinel node biopsy for breast cancer: incidence and clinical significance. Ann Surg Oncol 2005;12:29–33.
13.
Chung M, Steinhoff M, Cady B: Clinical axillary recurrence in breast cancer patients after a negative sentinel node biopsy. Am J Surg 2002;184:310–314.
14.
Newman LA, Hunt KK, Buchholz T, et al: Presentation, management and outcome of axillary recurrence from breast cancer. Am J Surg 2000;180:252–256.
15.
Reitsamer R, Peintinger F, Prokop E, Menzel C, Cimpoca W, Rettenbacher L: Sentinel lymph node biopsy alone without axillary lymph node dissection – follow-up of sentinel lymph node negative breast cancer patients. Eur J Surg Oncol 2003;29:221–223.
16.
Reitsamer R, Peintinger F, Prokop E, Rettenbacher L, Menzel C: 200 sentinel lymph node biopsies without axillary lymph node dissection – no axillary recurrences after a 3-year follow-up. Br J Cancer 2004;90:1551–1554.
17.
Roumen RM, Kuijt GP, Liem IH, Van Beek MW: Treatment of 100 patients with sentinel node-negative breast cancer without further axillary dissection. Br J Surg 2001;88:1639–1643.
18.
Rouzier R, Extra JM, Klijanienko J, et al: Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes. J Clin Oncol 2002;20:5–10.
19.
Sanjuan A, Vidal-Sicart S, Zanón G, et al: Clinical axillary recurrence after sentinel node biopsy in breast cancer: a follow-up study of 220 patients. Eur J Nucl Med Mol Imaging 2005;32:932–936.
20.
Snoj M, Bracko M, Zagar I: Axillary recurrence rate in breast cancer patients with negative sentinel lymph node. Croat Med J 2005;46:377–381.
21.
Torrenga H, Fabry H, Van der Sijp J, Van Diest P, Pijpers R, Meijer S: Omitting axillary lymph node dissection in sentinel node negative breast cancer patients is safe: a long term follow-up analysis. J Surg Oncol 2004;88:4–8.
22.
Van der Vegt B, Doting MHE, Jager PL, Wesseling J, De Vries J: Axillary recurrence after sentinel lymph node biopsy. Eur J Surg Oncol 2004;30:715–720.
23.
Veronesi U, Paganelli G, Galimberti G, et al: Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes. Lancet 1997;349:1864–1867.
24.
Veronesi U, Galimberti V, Mariani L, et al.: Sentinel node biopsy in breast cancer: early results in 953 patients with negative sentinel node biopsy and no axillary dissection. Eur J Cancer 2005;41:231–237.
25.
Viale G, Bosari S, Mazzarol G, et al: Intraoperative examination of axillary sentinel lymph nodes in breast carcinoma patients. Cancer 1999;85:2433–2438.
26.
Wright FC, Walker J, Law CH, McCready DR: Outcomes after localized axillary node recurrence in breast cancer. Ann Surg Oncol 2003;10:1054–1058.
27.
Zavagno G, Carcoforo P, Franchini Z, et al: Axillary recurrence after negative sentinel lymph node biopsy without axillary dissection: a study on 479 breast cancer patients. Eur J Surg Oncol 2005;31:715–720.
28.
Zurrida S, Orecchia R, Galimberti V, et al: Axillary radiotherapy instead of axillary dissection: a randomized trial. Italian Oncological Senology Group. Ann Surg Oncol 2002;9:156–160.
29.
Dessureault S, Dupont E, Shons A, et al: Early results of breast cancer lymphatic mapping from the H. Lee Moffit Cancer Center: no axillary recurrences in breast cancer patients after a negative sentinel lymph node biopsy. Breast Cancer Res Treat 2000;64:26.
30.
Schrenk P, Hatzl-Griesenhofer M, Shamiyeh A, Waynad W: Follow-up of sentinel node negative breast cancer patients without axillary lymph node dissection. J Surg Oncol 2001;77:165–170.
31.
Veronesi U, Galimberti V, Zurrida S, et al: Sentinel lymph node biopsy as an indicator for axillary dissection in early breast cancer. Eur J Cancer 2001;37:454–458.
32.
Shivers S, Cox C, Leight G, et al: Final results of the Department of Defense Multicenter Breast Lymphatic Mapping Trial. Ann Surg Oncol 2002;9:248–255.
33.
Hansen NM, Grube BJ, Giulano AE: The time has come to change algorithm for the surgical management of early breast cancer. Arch Surg 2002;137:1131–1135.
34.
Naik AM, Fey J, Gemignani M, et al: The risk of axillary relapse after sentinel lymph node biopsy for breast cancer is comparable with that of axillary lymph node dissection: a follow-up study of 4008 procedures. Ann Surg 2004;240:462–468.
35.
Loza J, Colo F, Nadal J, et al: Axillary recurrence after sentinel node biopsy for operable breast cancer. Eur J Oncol 2002;28:897–898.
36.
Estourgie SH, Nieweg OE, Valdes-Olmos RA, et al: Eight false negative sentinel node procedures in breast cancer: what went wrong? Eur J Surg Oncol 2003;29:336–340.
37.
Blanchard DK, Donohue JH, Reynolds C, Grant CS: Relapse and morbidity in patients undergoing sentinel lymph node biopsy alone or with axillary dissection for breast cancer. Arch Surg 2003;138:482–487.
38.
Badgwell BD, Povoski SP, Abdessalam SF, et al: Patterns of recurrence after sentinel lymph node biopsy for breast cancer. Ann Surg Oncol 2003;10:376–380.
39.
Veronesi U, Paganelli G, Viale G, et al: A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 2003;349:546–553.
40.
Winchester DJ, Sener SF, Brinkman EM, et al: Axillary recurrence following sentinel node biopsy. Ann Surg Oncol 2004;11:S58.
© 2007 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.